Post on 05-Apr-2018
7/31/2019 15 Mr. Alberto Diaz+++
1/33
Biotechnology
Industrial Biotechnology in Argentina:Enterprises and Potentialities
Alberto Daz
DirectorIndustrial Biotechnology Center INTI
Dias tecnolgicos Argentina Repblica Checa 2009 Nov., 25
7/31/2019 15 Mr. Alberto Diaz+++
2/33
Industrial Biotechnology Center
7/31/2019 15 Mr. Alberto Diaz+++
3/33
Industrial Biotechnology Center
BIOTECHNOLOGY PUBLIC SECTOR in Argentina
Tradition (school) in biomedicine, specially.
Nowadays: seeds and agrifoods.
Human Resources: education in biologicalsciences.
7/31/2019 15 Mr. Alberto Diaz+++
4/33
Industrial Biotechnology Center Biotechnology in Argentina. State actions:
Establishment of the Ministry for Science, Technology andProductive Innovation: 2007.
Law to Promote Modern Biotechnology: now being regulated.
Tenders to set up sectorial funds: health care, energy, agro-industries and social development.
Programmes to set up technology based enterprises; training ofhuman resources; sectorial funds for new technologies.
Importance of R&D in biomedicine. Agro foods.
7/31/2019 15 Mr. Alberto Diaz+++
5/33
Industrial Biotechnology Center PUBLIC SECTOR
PERSONNEL YEAR 2008Researchers: 5.661Scholarship holders: 6.598Technicians: 2.291
Total: 14.550 (Year 2003: 8.602)
Biologic and Health Care SciencesResearchers: 1.844Scholarship holders: 2.149I
Technicians: 710
Total: 4.703 (approx. 30 %)
7/31/2019 15 Mr. Alberto Diaz+++
6/33
Industrial Biotechnology Center
6.640 (45 % int. coop.).60004000
200720061998
Argentina. S.C.I. Publications
2007:Life Sciences: 2.281Clinical Medicine: 1604
7/31/2019 15 Mr. Alberto Diaz+++
7/33
Economic impacts of biotechnology
on the Argentinean economyPICT. 2002 Cdigo de proyecto 02-13063
7/31/2019 15 Mr. Alberto Diaz+++
8/33
OUTLINE OF ARGENTINE BIOTECHNOLOGICAL
PRIVATE FIRMS
100.00100.0084TOTAL
23.8111.3020Human Health
11.9015.3710Food Ingredients for Bioprocessing
11.9024.7810Animal Health
22.6241.0519Seeds and Plantines
29.777.5125InoculantsAgriculture and
livestock
Firms/Total FirmsParticipation
in biotechsales
Number ofFirms
Industry
Source: a)Extracted from the "Economic Impacts of Biotechnology on Agriculture, Food and
Health Industries in Argentina", Project PICT 2002 -2004 Code 02-13063 Database.b) Biotechnology and Development. A pattern to set up in Argentina Ed. Prometeo yUNGS - December 2006 .
- Quantity and percentage -
Industrial Biotechnology Center
7/31/2019 15 Mr. Alberto Diaz+++
9/33
INVESTMENT IN INNOVATION (R&D)
SELECTED PRIVATE BIOTECHNOLOGICALFIRMS ARGENTINA 2002/03-thousand pesos and percentages-
5.270.950,027950,1605,560,968TOTAL
15.555.216,696107,383321,175Human Health
1.450.892,112146,030237,140Food Ingredients
2.751.726,478235,425377,500
Animal
Health
5.940.5223,181390,0004,462,523Seeds2.190.961,56071,322162,630Vaccines
Agriculture
and
Livestock
Biological &
Biotechnologi
cal Sales
Total Sales
Biological &
Biotechnolo
gical
Total
Investment in R&D/
Investment
in R&D
Sales
Area
Note: * 71 firms were selected from the poll.
Source: Extracted from the "Economic Impacts of Biotechnology on Agriculture, Food and Health
Industries in Argentina", Project PICT 2002 - Code 02-13063 database.
7/31/2019 15 Mr. Alberto Diaz+++
10/33
7/31/2019 15 Mr. Alberto Diaz+++
11/33
Quilmes Natl Univ UNQUniv Buenos Aires UBA
Nat Acad Medicine
Natl Res Council CONICET
Garrahan Children Hosp
Roffo Oncology Inst
R+D in CancerStrategic ProgramConsortium of Public Institutions and Companies
ROMIKIN SA
ELEA SACIFyA
International Partners: Center of Molecular Immunology and Center
of Genetic Engineering and Biotecnology (Cuba); Europharma
(Brazil); Kalbe Biotech (Indonesia); Chemo France (France).
7/31/2019 15 Mr. Alberto Diaz+++
12/33
VEGF Vaccine(Solid tumors)
Products PreclinicalPhase
IPhase
IIPhase
III
Racotumomab vaccine(Lung cancer)
NGcGM3 Molecular vaccine(Breast cancer; melanoma)
VSSP Immunological adyuvant(HIV-Aids; cancer)
Anti-CK2 Proapoptotic peptide(Condiloma genital y Cncer crvicouterino)
Vasopressin Peptide analogs(Breast cancer surgery)
Anti-RhoGTPases Small compounds(Prostate and breast cancer; glioma)
Pipeline and development phases
Done
In course
To bestarted
7/31/2019 15 Mr. Alberto Diaz+++
13/33
Argentina: Evolucin de la superficie cultivada con OGM
0%
20%
40%
60%
80%
100%
96/97 97/98 98/99 99/00 00/01 01/02 02/03 03/04 04/05 05/06 06/07
Maz Algodn Soja
Fuente: ArgenBio, 2007
7/31/2019 15 Mr. Alberto Diaz+++
14/33
Argentina: evolucin de la superficie total con OGM(en millones de hectreas)
Fuente: ArgenBio, 2007
0,0
4,0
8,0
12,0
16,0
20,0
96/97
97/98
98/99
99/00
00/01
01/02
02/03
03/04
04/05
05/06
06/07
18,4
7/31/2019 15 Mr. Alberto Diaz+++
15/33
PROVEEDORES
DE TECNOLOG A
9%
PRODUCTORES76%
SEMILLA
4%
GLIFOSATO
5%
ESTADO
NACIONAL
15%
Beneficio Total Acumulado: 19.737,06 millones de dlares
Distribucin de los beneficios generados por laadopcin de la soja GM (1996-2005):
E. Trigo, E. Cap, 2007
7/31/2019 15 Mr. Alberto Diaz+++
16/33
LA RE-INVENCIN DE BIOCERES 2007
Un grupo de empresas que abarca toda la Cadena de Valor de la
Biotecnologa
.Desde el Campo al Laboratorio y desde el Laboratorio al
Campo.
BIOCERES S.A. se convierte en un Holding (Grupo)
7/31/2019 15 Mr. Alberto Diaz+++
17/33
GRUPO BIOCERES
7/31/2019 15 Mr. Alberto Diaz+++
18/33
BIOGNESIS - BAG Anual production capacity
Food Mouth Disease (FMD): 200 M doses
Bovine Vaccines: 100 M doses. Rage vaccine: 20 M doses
7/31/2019 15 Mr. Alberto Diaz+++
19/33
Conclusions A set of local private firms began to develop biotech products
and technology at 80.
In general are SME, financed with local capital.
Nowadays, approximately 70 private companies workingdeveloping biotech.
1996: first GMO approved.
There are in Argentine a relevant critical mass of firms withcapacities of further develop process, new products, joint
ventures and internationalization. There are a tradition (school) and relevant critical mass of
researchers in biomedicine with high capacity to development.
Industrial Biotechnology Center
7/31/2019 15 Mr. Alberto Diaz+++
20/33
7/31/2019 15 Mr. Alberto Diaz+++
21/33
7/31/2019 15 Mr. Alberto Diaz+++
22/33
CENTRO DE BIOTECNOLOGIA INDUSTRIAL DEL INTI.Primera Etapa
Dominar tecnologa bsica molecular y procesos
7/31/2019 15 Mr. Alberto Diaz+++
23/33
7/31/2019 15 Mr. Alberto Diaz+++
24/33
Centro de biotecnologia industrial INTI
Edificio 51: En los 51 aos de INTIDe la biologia molecular a la Biotecnologa
De la biotecnologa a la BioIndustria
7/31/2019 15 Mr. Alberto Diaz+++
25/33
7/31/2019 15 Mr. Alberto Diaz+++
26/33
Industrial Biotechnology Center
7/31/2019 15 Mr. Alberto Diaz+++
27/33
Industrial Biotechnology Center Las Abuelas (Grandmothers) and Genetics: the
contribution of science to the identification of the childrenof the desaparecidos.
An example of the successful result of biotechnology, with animportant ethical and social repercussion.
It shows that social demands also produce innovation and usefulresults.
It pressed scientists to provide urgent responses. It may become an example for enterprises to carry out R&D:
knowledge; time; adequate funding.
INTERNATIONAL COOPERATION WAS NECESSARY
7/31/2019 15 Mr. Alberto Diaz+++
28/33
Thank you
7/31/2019 15 Mr. Alberto Diaz+++
29/33
7/31/2019 15 Mr. Alberto Diaz+++
30/33
Cooperacin Comunidad Europea - MERCOSUR
7/31/2019 15 Mr. Alberto Diaz+++
31/33
Empresas Biotecnolgicas en Argentinaseleccionadas 2002/2003
10085Totales
11,3020Salud Humana
15,3710IngredientesAlimentos
24,7810Sanidad Animal
41,0520Semillas/Plantines7,5125Inoculantes
% Ventas BiotecTotal (N)Sector
7/31/2019 15 Mr. Alberto Diaz+++
32/33
Biotechnology companies in Argentina2002/2003
10085Total
11.3020Human Health
15.3710Food
ingredients
24.7810Animal Health
41.0520Seeds/Micropr.
7.5125Inoculants
% Sale Biotech.Total (N)Sector
7/31/2019 15 Mr. Alberto Diaz+++
33/33